Ductal Carcinoma In Situ: A Rose by Any Other Name

Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA (DLW, TBJ).
Journal of the National Cancer Institute (Impact Factor: 12.58). 09/2013; 105(20). DOI: 10.1093/jnci/djt268
Source: PubMed
8 Reads
  • Source
    • "Breast cancer is among the most common cancers with worldwide more than 1,300,000 cases each year (Cancer and Atlas, 2012). Among these cases, ductal carcinoma, a particular subtype of breast cancer, represents up to 25% of all newly diagnosed patients in the United States (Wickerham and Julian, 2013). In general, breast cancer is derived from epithelial cells that develop neoplasia in breast tissue. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we infer the breast cancer gene regulatory network from gene expression data. This network is obtained from the application of the BC3Net inference algorithm to a large-scale gene expression data set consisting of 351 patient samples. In order to elucidate the functional relevance of the inferred network, we are performing a Gene Ontology (GO) analysis for its structural components. Our analysis reveals that most significant GO-terms we find for the breast cancer network represent functional modules of biological processes that are described by known cancer hallmarks, including translation, immune response, cell cycle, organelle fission, mitosis, cell adhesion, RNA processing, RNA splicing and response to wounding. Furthermore, by using a curated list of census cancer genes, we find an enrichment in these functional modules. Finally, we study cooperative effects of chromosomes based on information of interacting genes in the beast cancer network. We find that chromosome 21 is most coactive with other chromosomes. To our knowledge this is the first study investigating the genome-scale breast cancer network.
    Full-text · Article · Feb 2014 · Frontiers in Genetics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study measures the probability of development of invasive breast cancer (BC) following the diagnosis of carcinomas in situ (CIS). A 25-year prospective follow-up was conducted by linking the Canadian National Breast Screening Study (CNBSS) to cancer registries and a national vital statistics database. Subsequent BC incidence was identified in CNBSS women who were diagnosed with CIS. CIS was classified into ductal (DCIS) and lobular carcinoma in situ (LCIS). Cumulative cancer incidence probabilities were calculated and a 1:5 matched nested case control study was conducted to estimate the odds of BC development. Of the 146 women diagnosed with CIS, 26 developed invasive BC (17.8%) and 12 died of BC (8.2%). The average time from the diagnosis of CIS to invasive BC was 6.3 years (±5.6). The 20-year cumulative incidence probabilities for DCIS and LCIS were 19.0% (95%CI: 11.2, 26.8) and 21.3% (95%CI: 7.1, 35.4) respectively. The odds of development of BC in CIS women was significantly elevated compared to controls (OR=2.6, 95% CI: 1.5, 4.5). While women with CIS had a higher odds of development of BC compared to those without CIS, at 20-year post CIS diagnosis, more than 80% of them remained free of invasive BC. This low probability of developing invasive BC post CIS diagnosis does not support the notion that CIS of the breast is an obligate precursor lesion of invasive BC. © 2014 Wiley Periodicals, Inc.
    Full-text · Article · Feb 2014 · International Journal of Cancer

  • No preview · Article · May 2014 · Journal of the American College of Radiology: JACR
Show more